List view / Grid view
30 January 2023 | By Catherine Eckford (European Pharmaceutical Review)
Four new medicines were recommended for approval at the Committee for Medicinal Products for Human Use (CHMP)’s January meeting, with positive opinions given to two type 2 diabetes drugs.
18 October 2011 | By GlaxoSmithKline
RTS,S* reduces the risk of malaria by half...
25 April 2013 | By Novartis
"We believe that this innovative campaign will help speed malaria elimination..."
28 November 2013 | By Novartis
Novartis scientists have discovered a new drug target for treating malaria...
9 November 2012 | By GlaxoSmithKline
Results from ongoing Phase III clinical trial announced...
5 May 2011 | By Sanofi-Aventis
Sanofi-aventis and MMV announced that they have signed an alliance agreement...
12 November 2014 | By Novartis
Novartis announced that, through Power of One, enough funds have been raised to deliver three million antimalarial treatments for children in Zambia...
27 January 2023 | By Catherine Eckford (European Pharmaceutical Review)
Based on recent research, a "potential game changer” approach could offer a practical way to use monoclonal antibody therapies for malaria in Africa.
2 December 2020 | By Hannah Balfour (European Pharmaceutical Review)
The WHO’s World malaria report suggests the progress in eradicating malaria has slowed due to funding shortages and that COVID-19 disruptions could result in additional deaths.
28 June 2010 | By AstraZeneca
AstraZeneca and Medicines for Malaria Venture (MMV) today announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria...
8 July 2015 | By Victoria White
Sanofi is to extend its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new single, fixed-dose combination therapy for malaria...
8 October 2013 | By GlaxoSmithKline
These latest results demonstrated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases...
12 August 2021 | By Anna Begley (European Pharmaceutical Review)
One dose of a monoclonal antibody developed at the US National Institutes of Health (NIH) prevented malaria for up to nine months.
29 November 2011 | By Sanofi
Sanofi organizes the 10th Edition of the Pan-African Conference against Malaria with representatives of 34 African Countries...
22 August 2022 | By Hannah Balfour (European Pharmaceutical Review)
Securing 18 million doses of GSK’s RTS,S malaria vaccine, UNICEF calls the contract a major breakthrough for child health.
